The Canadian Drug Expert Committee (CDEC) has recommended that teriflunomide not be listed at the submitted price. 

Reasons for the Recommendation: 

1. Two randomized controlled trials (RCTs) (TOWER and TEMSO) demonstrated that the annualized relapse rate was lower with teriflunomide compared with placebo for patients with relapsing-remitting multiple sclerosis (RRMS) and one RCT (TENERE) demonstrated no statistically significant difference in the annualized relapse rate between teriflunomide and interferon beta-1a. 

2. At the submitted price, teriflunomide is more costly than glatiramer acetate and interferon beta-1b. CDEC concluded that, without evidence demonstrating superior clinical benefit with teriflunomide compared with other available treatments for RRMS, a higher cost for teriflunomide is not justified. 

Based on a review of the clinical evidence, CDEC noted that a reduction in price would increase the likelihood of a recommendation to list or list with clinical criteria and/or conditions.

For more details, go to: http://www.cadth.ca/media/cdr/complete/SR0350_complete_Aubagio_Jun-19-14.pdf